[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"staphylococcal-aureus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:staphylococcal-aureus-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100633300","phase-2-staph-nasal-decolonization-to-improve-function-and-feeding-100633300",false,"NCT07524894","Staph Nasal Decolonization to Improve Function and Feeding","Staph Nasal Decolonization to Improve Function and Feeding: A Randomized Clinical Trial (SNIFF)","SNIFF","Inclusion Criteria:\n\n* Histologically confirmed mucosal squamous cell carcinoma of the head and neck, planned to receive a dose equivalent to 60 Gy in 30 fractions or higher, with or without concurrent systemic treatment. This can include hypofractionated regimens of 55 Gy in 20 fractions. Primary sites considered: oral cavity, oropharynx, larynx (excluding T1-T2N0 glottic cancers), hypopharynx. The radiotherapy treatment planned can be definitive or adjuvant.\n* Age ≥18 years.\n* ECOG performance status 0-2\n* Informed consent provided.\n\nExclusion Criteria:\n\n* Mupirocin allergy\n* Skin or salivary gland malignancy\n* Early stage glottic cancers (T1-2N0)","ALL","18 Years",{"count":20,"type":21},126,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Radiation therapy is a type of treatment that involves using radiation beams targeted at a cancer to destroy the cancer cells or slow their growth. This type of treatment has helped many cancer patients for decades and is intended to kill cancer cells directly. Patients with head and neck cancer are commonly treated with radiation, sometimes after surgery and sometimes the radiation is delivered with chemotherapy at the same time. Radiation treatments have side effects, and the treating oncologist works with each patient to determine the best treatment and manage the side effects.\n\nIt has been shown that one of these side effects of radiation is irritation or \"sunburn\" of the lining of the mouth and throat (radiation mucositis), which can cause difficult or painful swallowing, and pain\u002Fdiscomfort in the mouth\u002Fthroat. These side effects can lead to dehydration, and weight loss, and sometimes can lead to hospital admissions and treatment delays. This is usually treated by the prescription of pain relievers, dietician support and, if necessary, nutrition via a tube (G-tube).\n\nBecause of these symptoms involving the mouth and throat, researchers are looking to study the effect of a common ointment antibiotic used to reduce an infection known as Staphylococcus Aureus. The infection is commonly located in the front of the nose, and during treatment this infection can travel from the nose to the throat and worsen the radiation mucositis and the pain it causes. The study will measure if a course of ointment antibiotic in the nose (twice per day, 5 days on, 5 days off, repeated) can reduce your pain during treatment by reducing severe mucositis related to Staphylococcal infection. This study compares the effects of the study treatment with a \"placebo,\" which looks the same but does not contain any active medicine. Neither you nor your doctor will know which one you are receiving until the study ends. The antibiotic used in the study arm is being used \"off-label\" for intranasal application (it is normally used to treat skin infections). Possible side effects include local skin irritation or allergic reactions, and in rare cases, a severe allergic response (anaphylaxis).",[27,28,29],"Radiation Mucositis","Staphylococcal Aureus Infection","Head and Neck Cancer","NOT_YET_RECRUITING","2026-04-27",{"date":33,"type":34},"2026-05-01","ACTUAL",{"date":36,"type":21},"2026-06-01",{"date":38,"type":21},"2028-01-30",{"name":40,"class":41},"David Palma","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":42},"100578030","phase-1-administering-nmt-to-reestablish-infant-nasal-microbiome-diversity-following-intranasal-mupirocin-treatment-100578030","NCT06805994","Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment","Parent-to-Child Nasal Microbiota Transplant to Reestablish Nasal Microbiome Diversity After Intranasal Mupirocin Treatment of Children With Staphylococcus Aureus Nasal Colonization","NMT Protocol 3","Child:\n\nInclusion criteria\n\n1. Child has had a prior nasal surveillance culture grow S. aurues\n2. Child is \\\u003C18 years of age\n3. Child completed treatment with intranasal mupirocin for S. aureus nasal colonization as part of routine clinical care two or more days before the planned transplant\n4. Child has anticipated hospital length of stay \\>3 days after completing intranasal mupirocin treatment\n5. Infant \\>25 weeks gestation unless \\>2 months chronological age\n\nExclusion criteria\n\n1. Child is a ward of the State\n2. Child with a diagnosis of immunodeficiency or antenatal suspicion for immunodeficiency (e.g., sibling with known immunodeficiency, genetic syndrome with known associated immunodeficiency)\n3. Child cannot have nasal swabs collected (due to anatomic or other clinical intervention, including nasal packing)\n\nDonor:\n\nInclusion criteria\n\n1. Donor is able to provide informed consent\n2. Donor has a relationship with the child outside of the hospital setting (i.e., not an ICU caregiver)\n\nExclusion criteria\n\n1. Donor had positive COVID-19 test in prior 21 days\n2. Donor with signs or symptoms of respiratory illness (e.g. runny nose, congestion, fever, cough)\n3. Donor has been in close contact with someone in the last 7 days who had a respiratory viral infection (e.g., cold, flu)\n4. Donor tests positive on baseline screening test for S. aureus nasal colonization.\n5. Donor tests positive on baseline screening test for a respiratory pathogen.\n6. Donor is not able to provide written informed consent\n7. Donor is not able to be present at the bedside at the time of intervention.\n8. Donor has history of chronic sinusitis, cystic fibrosis, or an infection with a multi-drug resistant organism.\n9. Inability or unwillingness to complete the Donor questionnaire or a positive response to any question on the Donor questionnaire.\n10. Donor has smoked within the last month",true,"0 Years","60 Years",{"count":55,"type":21},175,[57],"PHASE1","This protocol aims to evaluate how NMT affects pediatric nasal microbiome diversity following intranasal mupirocin treatment",[28,60,61,62,63],"Microbial Colonization","Pediatric Infection","S. Aureus Colonization","Microbial Transplant",[65,66,67],"microbiome","s. aureus","staph","RECRUITING","2025-08-27",{"date":71,"type":34},"2025-09-04",{"date":69,"type":34},{"date":74,"type":21},"2028-01-01",{"name":76,"class":41},"Johns Hopkins University"]